And considered CAR T cells directed against murine CD4 as a promising strategy for AITL patients since ex vivo generated anti-CD4CAR NK or T cells were able to eliminate human T-cell leukemia and lymphoma in preclinical mouse models [41, 42]. This evidence concerns the gene CD4 and lymphoma.